2-[3-(二异丙胺基)-1-苯丙基l]-4-甲基苯酚 | 124936-74-9

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-[3-(二异丙胺基)-1-苯丙基l]-4-甲基苯酚
• 中文别名: 2-[3-[双(1甲基乙基-)氨基]-1-苯基丙基]-4-甲基苯酚溴氢酸盐；氢溴酸托特罗定
• 英文名称: N,N-diiso-propyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine
• 英文别名: tolterodine；RS-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine；2-(3-(Diisopropylamino)-1-phenylpropyl)-4-methylphenol；2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol
• CAS: 124936-74-9
• 化学式: C₂₂H₃₁NO
• 分子量: 325.494
• InChiKey: OOGJQPCLVADCPB-UHFFFAOYSA-N

物化性质

• 熔点：
  72.3-73.5 °C
• 沸点：
  442.2±45.0 °C(Predicted)
• 密度：
  1.003±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2922299090

反应信息

• 作为反应物：
  描述：

  2-[3-(二异丙胺基)-1-苯丙基l]-4-甲基苯酚 在 盐酸 、 sodium carbonate 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 3.5h， 生成 (R)-托特罗定L-酒石酸盐
  参考文献：
  名称：

  Ligand–Phospholipid Conjugation: A Versatile Strategy for Developing Long-Acting Ligands That Bind to Membrane Proteins by Restricting the Subcellular Localization of the Ligand

  摘要：

  We hypothesized that if drug localization can be restricted to a particular subcellular domain where their target proteins reside, the drugs could bind to their target proteins without being metabolized and/or excreted, which would significantly extend the half-life of the corresponding drug target complex. Thus, we designed ligand phospholipid conjugates in which the ligand is conjugated with a phospholipid through a polyethylene glycol linker to restrict the subcellular localization of the ligand in the vicinity of the lipid bilayer. Here, we present the design, synthesis, pharmacological activity, and binding mode analysis of ligand phospholipid conjugates with muscarinic acetylcholine receptors as the target proteins. These results demonstrate that ligand phospholipid conjugation can be a versatile strategy for developing long-acting ligands that bind to membrane proteins in drug discovery.

  DOI：

  10.1021/acs.jmedchem.8b00041
• 作为产物：
  描述：

  (+/-)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenyl-propanamide 在 lithium aluminium tetrahydride 、 水 、 溶剂黄146 作用下， 以 乙醚 为溶剂， 反应 96.0h， 生成 2-[3-(二异丙胺基)-1-苯丙基l]-4-甲基苯酚
  参考文献：
  名称：

  Process for the preparation of tolterodine

  摘要：

  一种用于制备托特罗定（即(R)-N,N-二异丙基-3-(2-羟基-5-甲基苯基)-3-苯丙胺）的新型方法，以其外消旋形式为基础，并提供了制备该化合物的中间体。

  公开号：

  US20060189827A1

文献信息

• Medicament Combinations for the Treatment of Respiratory Diseases
  申请人：Konetzki Ingo

  公开号：US20070203125A1

  公开（公告）日：2007-08-30

  The present invention relates to new medicament combinations which contain in addition to one or more, preferably one compound of general formula 1 wherein A, B, R 1 , X, n and m may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

  本发明涉及新的药物组合物，除了一个或多个，最好是1号通用公式中的一个化合物外，其中A、B、R1、X、n和m的含义如权利要求和说明书中所给，至少还包含另一种活性物质2，以及它们的制备方法和作为药物组合物的用途。
• PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES
  申请人：Konetzki Ingo

  公开号：US20080051392A1

  公开（公告）日：2008-02-28

  The present invention relates to new pharmaceutical combinations which contain in addition to one or more, preferably one compound of general formula 1 wherein the groups R 1 , R 2 and R 3 may have the meanings given in the claims and specification, at least one further active substance 2, processes for preparing them and their use as medicaments.

  本发明涉及包含除了一个或多个一般式1的化合物之外，至少一个进一步的活性物质2的新药物组合，其中R1、R2和R3基团可能具有权利要求和说明书中给定的含义，以及其制备方法和作为药物的用途。
• ENANTIOMERICALLY PURE BETA AGONISTS, MANUFACTURING AND USE THEREOF
  申请人：KONETZKI Ingo

  公开号：US20080070909A1

  公开（公告）日：2008-03-20

  The present invention relates to enantiomerically pure compounds of formula 1 wherein the groups R 1 , R 2 , R 3 , m and Y m− may have the meanings given in the claims and specification, processes for preparing them and their use as medicaments, particularly as medicaments for the treatment of respiratory complaints.

  本发明涉及具有公式1的立体纯化合物，其中R1、R2、R3、m和Ym−可以具有如权利要求和说明书中所给出的含义，以及用于制备它们的方法以及它们作为药物的使用，尤其是作为治疗呼吸系统疾病的药物。
• METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS
  申请人：TUFTS MEDICAL CENTER

  公开号：US20160052982A1

  公开（公告）日：2016-02-25

  The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest.

  本申请提供了制备可溶性脂质化配体药剂的方法，包括配体实体和脂质实体，并在某些实施例中提供了这些组分的相关参数，从而使得能够适当选择组分来组装出针对任何感兴趣的靶点的活性药剂。
• PROCESS FOR THE PREPARATION OF 2-HYDROXY-4-PHENYL-3,4-DIHYDRO-2H-CHROMEN-6-YL-METHANOL AND (R)-FESO-DEACYL
  申请人：Ciambecchini Umberto

  公开号：US20130079532A1

  公开（公告）日：2013-03-28

  The present invention regards an improved and industrially advantageous process for the preparation of the 2-hydroxy-4-phenyl-3,4-dihydro-2H-chromen-6-yl-methanol intermediates, also called “feso chromenyl” and (R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenol, also called “(R)-feso deacyl”, which are in turn used in the synthesis of fesoterodine and in particular of fesoterodine fumarate. This process utilises reagents which are non-toxic and manageable at industrial level and enables obtaining a new stable and non-hygroscopic crystalline form of the key intermediate “(R)-feso deacyl”, called form B.

  本发明涉及一种改进的且在工业上有利的2-羟基-4-苯基-3,4-二氢-2H-色原-6-基甲醇中间体的制备过程，也称为“feso色原”和(R)-2-[3-(二异丙氨基)-1-苯基丙基]-4-(羟甲基)苯酚，也称为“(R)-feso脱酰”，后者用于合成长效毒蕈碱类药物非索特罗定及其特别是非索特罗定富马酸盐。该过程使用在工业水平上无毒且易于处理的试剂，并且能够获得一种新的稳定且非吸湿性的关键中间体“(R)-feso脱酰”的晶型B。